Xin Lang Cai Jing·2026-02-09 11:34Core Viewpoint - Recent earnings forecasts from listed vitamin companies indicate a mixed outlook for 2025, with Nengte Technology and Brothers Technology expecting profits, while Guangji Pharmaceutical anticipates significant losses [1][11]. Group 1: Nengte Technology - Nengte Technology forecasts a net profit of 200 million to 250 million yuan for 2025, a significant recovery from a loss of 588 million yuan in the previous year [2][11]. - The increase in profit is primarily driven by a substantial growth in the vitamin E business, which is expected to contribute no less than 660 million yuan [2][11]. - However, the pharmaceutical intermediates business underperformed, with lower-than-expected sales of Montelukast sodium intermediates and ongoing price competition in the market for Rosuvastatin intermediates, leading to a proposed goodwill impairment of up to 260 million yuan [2][12]. Group 2: Brothers Technology - Brothers Technology anticipates a net profit of 85 million to 110 million yuan for 2025, representing a year-on-year growth of 108.26% to 169.52% [4][11]. - The expected growth is attributed to price increases in certain vitamin products, higher production and sales volumes of phenol derivatives, and a reduction in costs for some products [4][11]. Group 3: Guangji Pharmaceutical - Guangji Pharmaceutical projects a net loss of 399 million to 518 million yuan for 2025, compared to a loss of 295 million yuan in the previous year [5][11]. - The company cites intensified market competition as a key factor, resulting in prolonged low sales prices for its main products and underperformance in capacity utilization and overall operational results [5][11].